2024 World Conference on Lung Cancer (WCLC) - Posters-P1.06B.03 Genetic Profiles and Evolutionary Trajectory of Early-Stage Lung Adenocarcinoma (AAH,AIS,MIA and IA) revealed by Multiplex Sequencing

P1.06B.03 Genetic Profiles and Evolutionary Trajectory of Early-Stage Lung Adenocarcinoma (AAH,AIS,MIA and IA) revealed by Multiplex Sequencing

Back to course

Pdf Summary

The study "Genetic profiles and evolutionary trajectory of early-stage lung adenocarcinoma (AAH, AIS, MIA, and IA) revealed by multiplex sequencing" explores the genetic mutations associated with the progression of lung adenocarcinoma using multiplex sequencing techniques. Following the PRISMA guidelines, the researchers conducted a comprehensive review by analyzing data sourced from PubMed and Web of Science as of August 2023. They examined 5,315 samples across 16 articles to map out gene mutation patterns from atypical adenomatous hyperplasia (AAH) to invasive adenocarcinoma (IA).<br /><br />The findings reveal a progressive increase in EGFR and TP53 mutations as lung adenocarcinoma evolves: mutation rates rose from 24.4% and 5.4% at the AAH or adenocarcinoma in situ (AIS) stages to 45.5% and 8.4% at the minimally invasive adenocarcinoma (MIA) stage, and further to 51.3% and 26.9% at the IA stage. Consistent mutation levels of EGFR were found using both next-generation sequencing and polymerase chain reaction methods, supporting the reliability of these techniques.<br /><br />A specific focus on the Chinese subgroup confirmed a similar increasing mutation trend. Distinct EGFR mutations, such as EGFR-L858R and EGFR-19Del, also showed substantial increases as the disease progressed from AAH/AIS through MIA to IA.<br /><br />The study concludes that while certain EGFR and TP53 mutations may not be the initiation events for lung adenocarcinoma, they significantly contribute to the early evolution and invasiveness of the disease. The research underscores the need for more extensive data to better understand the gene spectrum involved in the transition to invasive adenocarcinoma, indicating a crucial step in targeting early LUAD treatment and prevention strategies.

Asset Subtitle

lin lixuan

Meta Tag

Speaker lin lixuan

Topic Pathology & Biomarkers

Keywords

lung adenocarcinoma

genetic mutations

multiplex sequencing

EGFR mutations

TP53 mutations

evolutionary trajectory

early-stage cancer

PRISMA guidelines

next-generation sequencing

Chinese subgroup